探讨混合作用 κ/μ 阿片受体双位点调节剂的变构调节的假定机制。
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
机构信息
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Center for Substance Abuse Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.
出版信息
Future Med Chem. 2021 Mar;13(6):551-573. doi: 10.4155/fmc-2020-0308. Epub 2021 Feb 16.
Abstract
The modulation and selectivity mechanisms of seven mixed-action kappa opioid receptor (KOR)/mu opioid receptor (MOR) bitopic modulators were explored. Molecular modeling results indicated that the 'message' moiety of seven bitopic modulators shared the same binding mode with the orthosteric site of the KOR and MOR, whereas the 'address' moiety bound with different subdomains of the allosteric site of the KOR and MOR. The 'address' moiety of seven bitopic modulators bound to different subdomains of the allosteric site of the KOR and MOR may exhibit distinguishable allosteric modulations to the binding affinity and/or efficacy of the 'message' moiety. Moreover, the 3-hydroxy group on the phenolic moiety of the seven bitopic modulators induced selectivity to the KOR over the MOR.
摘要
七种混合作用κ阿片受体（KOR）/μ阿片受体（MOR）双靶点调节剂的调节和选择性机制进行了研究。分子建模结果表明，七种双靶点调节剂的“信息”部分与 KOR 和 MOR 的正位点具有相同的结合模式，而“地址”部分与 KOR 和 MOR 的变构位点的不同亚域结合。七种双靶点调节剂的“地址”部分与 KOR 和 MOR 的变构位点的不同亚域结合，可能对“信息”部分的结合亲和力和/或效力表现出可区分的变构调节作用。此外，七种双靶点调节剂中酚部分上的 3-羟基基团诱导对 KOR 的选择性，而不是 MOR。
相似文献
1
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
Future Med Chem. 2021 Mar;13(6):551-573. doi: 10.4155/fmc-2020-0308. Epub 2021 Feb 16.
2
Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
J Comput Aided Mol Des. 2020 Aug;34(8):879-895. doi: 10.1007/s10822-020-00309-x. Epub 2020 Mar 19.
3
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
J Med Chem. 2013 Nov 27;56(22):9156-69. doi: 10.1021/jm4012214. Epub 2013 Nov 7.
4
Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.
Elife. 2021 Feb 8;10:e56519. doi: 10.7554/eLife.56519.
5
Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Bioorg Med Chem. 2013 Nov 1;21(21):6405-13. doi: 10.1016/j.bmc.2013.08.042. Epub 2013 Sep 4.
6
Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.
Eur J Pharmacol. 2001 Mar 2;414(2-3):189-95. doi: 10.1016/s0014-2999(01)00822-6.
7
Structural biology: How opioid drugs bind to receptors.
Nature. 2012 May 16;485(7398):314-7. doi: 10.1038/485314a.
8
Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models.
Neurochem Res. 1996 Nov;21(11):1287-94. doi: 10.1007/BF02532369.
9
Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors.
Mol Pharmacol. 2018 Feb;93(2):157-167. doi: 10.1124/mol.117.109561. Epub 2017 Dec 12.
10
Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal κ- and μ-opioid receptor heterodimerization and female-specific spinal morphine antinociception.
J Neurosci. 2011 Aug 17;31(33):11836-45. doi: 10.1523/JNEUROSCI.1901-11.2011.
引用本文的文献
1
Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.
J Med Chem. 2024 Jun 13;67(11):9552-9574. doi: 10.1021/acs.jmedchem.4c00646. Epub 2024 May 30.
2
NCP, a Dual Kappa and Mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties.
J Pharmacol Exp Ther. 2024 Mar 15;389(1):106-117. doi: 10.1124/jpet.123.001870.
3
Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.
Pharmaceuticals (Basel). 2022 Feb 10;15(2):214. doi: 10.3390/ph15020214.
4
Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery.
Handb Exp Pharmacol. 2022;271:41-64. doi: 10.1007/164_2021_461.
本文引用的文献
1
Shedding light on the structural properties of lipid bilayers using molecular dynamics simulation: a review study.
RSC Adv. 2019 Feb 6;9(8):4644-4658. doi: 10.1039/c8ra08441f. eCollection 2019 Jan 30.
2
Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between Agonist Bias and Pharmacological Effects.
ACS Chem Neurosci. 2020 Oct 7;11(19):3036-3050. doi: 10.1021/acschemneuro.0c00407. Epub 2020 Sep 24.
3
Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Psychopharmacology (Berl). 2020 Aug;237(8):2405-2418. doi: 10.1007/s00213-020-05543-7. Epub 2020 May 20.
4
Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
J Comput Aided Mol Des. 2020 Aug;34(8):879-895. doi: 10.1007/s10822-020-00309-x. Epub 2020 Mar 19.
5
The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist.
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5836-5843. doi: 10.1073/pnas.1910006117. Epub 2020 Mar 3.
6
Recent Insights from Molecular Dynamics Simulations for G Protein-Coupled Receptor Drug Discovery.
Int J Mol Sci. 2019 Aug 29;20(17):4237. doi: 10.3390/ijms20174237.
7
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Brain Res. 2019 Dec 1;1724:146410. doi: 10.1016/j.brainres.2019.146410. Epub 2019 Aug 27.
8
Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.
Front Psychiatry. 2019 Jul 24;10:509. doi: 10.3389/fpsyt.2019.00509. eCollection 2019.
9
Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.
Molecules. 2018 Oct 11;23(10):2602. doi: 10.3390/molecules23102602.
10
Molecular Dynamics Simulation for All.
Neuron. 2018 Sep 19;99(6):1129-1143. doi: 10.1016/j.neuron.2018.08.011.
Zotero 插件